Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790803 · ClinicalTrials.gov registry record · NA
Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
A NA study, sponsored by Wake Forest University.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT00790803 is a NA study that has completed, run by Wake Forest University. The registered enrollment target is 5 participants.
The verdict
NCT00790803, a NA study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
According to a recent estimate more than 280,000 people in the United States are affected by uveitis each year. This report, also estimated that uveitis is the reason for 30,000 new cases of blindness/year and up to 10 percent of all cases of blindness. The purpose of this trial is to determine the effectiveness of VEGF blockade with intravitreal pegaptanib in patients with uveitic CME.
Interventions
- DRUG Pegaptanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790803
The ClinicalTrials.gov registry entry for NCT00790803 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegaptanib is the first listed.
NCT00790803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790803 about?
NCT00790803 is a clinical study titled "Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema". According to a recent estimate more than 280,000 people in the United States are affected by uveitis each year. This report, also estimated that uveitis is the reason for 30,000 new cases of blindness/year and up to 10 percent of all cases of blindness. The purpose of this trial is to determine the ...
What is the current status of trial NCT00790803?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2009-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00790803?
The interventions under investigation include: Pegaptanib (DRUG).
Who is sponsoring clinical trial NCT00790803?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.